Search by Drug Name or NDC

    NDC 00310-1730-85 FASENRA 30 mg/mL Details

    FASENRA 30 mg/mL

    FASENRA is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is BENRALIZUMAB.

    Product Information

    NDC 00310-1730
    Product ID 0310-1730_ec74f450-77c9-4e72-9111-7169441ced13
    Associated GPIs 4460402000E520
    GCN Sequence Number 077921
    GCN Sequence Number Description benralizumab SYRINGE 30 MG/ML SUBCUT
    HIC3 Z23
    HIC3 Description INTERLEUKIN-5(IL-5) RECEPTOR ALPHA ANTAGONIST, MAB
    GCN 44088
    HICL Sequence Number 044635
    HICL Sequence Number Description BENRALIZUMAB
    Brand/Generic Brand
    Proprietary Name FASENRA
    Proprietary Name Suffix n/a
    Non-Proprietary Name Benralizumab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 30
    Active Ingredient Units mg/mL
    Substance Name BENRALIZUMAB
    Labeler Name AstraZeneca Pharmaceuticals LP
    Pharmaceutical Class Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA], Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761070
    Listing Certified Through 2024-12-31

    Package

    NDC 00310-1730-85 (00310173085)

    NDC Package Code 0310-1730-85
    Billing NDC 00310173085
    Package 1 SYRINGE, GLASS in 1 CARTON (0310-1730-85) / 1 mL in 1 SYRINGE, GLASS
    Marketing Start Date 2017-11-14
    NDC Exclude Flag N
    Pricing Information N/A